OLN Stock Analysis: Olin | NYSE
Chemicals | NYSE, USA | Market Cap: 1.829m USD | 12M Return: -6.1% | US6806652052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 65.7M
Qual. Beats: 0
Rev. Trend: 34.8%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Olin Corporation is a U.S.-based chemical manufacturer incorporated in 1892 and headquartered in Clayton, Missouri, operating across the United States, Europe, Asia Pacific, the Middle East, Africa, India, Latin America, and Canada. The company is classified within the GICS Materials sector and the Commodity Chemicals sub-industry, reflecting its exposure to cyclical commodity pricing.
The company operates through three reportable segments: Chlor Alkali Products and Vinyls, which produces chlorine, caustic soda, and related vinyls; Epoxy, which supplies allylics, aromatics, and epoxy resins; and Winchester, which manufactures sporting, small caliber military, and industrial ammunition. Commodity chemicals producers like Olin are typically sensitive to feedstock costs and capacity utilization, with margins influenced by the supply-demand balance in chlor-alkali and epoxy value chains.
Olins customer base spans industrial users, mass merchants, retailers, wholesalers, gun clubs, and the U.S. Government and its prime contractors. The combination of bulk commodity chemicals and branded ammunition creates a portfolio that pairs cyclical industrial exposure with consumer and defense-oriented demand from the Winchester segment.
- ECU spreads tighten as chlorine demand weakens in housing sector
- Winchester ammunition sales surge on hunting and self-defense demand
- Natural gas and electricity costs pressure chlor-alkali margins
| Net Income: -167.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.99 > 1.0 |
| NWC/Revenue: 10.20% < 20% (prev 11.97%; Δ -1.78% < -1%) |
| CFO/TA 0.04 > 3% & CFO 321.2m > Net Income -167.6m |
| Net Debt (3.56b) to EBITDA (437.3m): 8.15 < 3 |
| Current Ratio: 1.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.0m) vs 12m ago -0.52% < -2% |
| Gross Margin: 6.68% > 18% (prev 9.25%; Δ -2.58% > 0.5%) |
| Asset Turnover: 89.80% > 50% (prev 89.29%; Δ 0.50% > 0%) |
| Interest Coverage Ratio: -0.24 > 6 (EBIT TTM -42.1m / Interest Expense TTM 178.2m) |
| A: 0.09 (Total Current Assets 2.20b - Total Current Liabilities 1.51b) / Total Assets 7.41b |
| B: 0.27 (Retained Earnings 1.99b / Total Assets 7.41b) |
| C: -0.01 (EBIT TTM -42.1m / Avg Total Assets 7.50b) |
| D: 0.30 (Book Value of Equity 1.72b / Total Liabilities 5.69b) |
| Altman-Z'' = 1.76 = BBB |
| DSRI: 0.96 (Receivables 1.02b/1.08b, Revenue 6.74b/6.79b) |
| GMI: 1.39 (GM 9.25% / 6.68%) |
| AQI: 1.01 (AQ_t 0.38 / AQ_t-1 0.37) |
| SGI: 0.99 (Revenue 6.74b / 6.79b) |
| TATA: -0.07 (NI -167.6m - CFO 321.2m) / TA 7.41b) |
| Beneish M = -2.72 (Cap -4..+1) = A |
As of November 08, 2026, the stock is trading at USD 17.31 with a total of 3,926,522 shares traded. Over the past week, the price has changed by -1.65%, over one month by +6.79%, over three months by -6.56% and over the past year by -6.14%.
Current recommended Stop Loss: 15.90 (which is 8.1% or 1.8 ATR below the current price).
Olin has received a consensus analysts rating of 3.13. Therefore, it is recommended to hold OLN.
- StrongBuy: 1
- Buy: 1
- Hold: 13
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 19.3 | 11.2% |
P/E Forward = 74.6269
P/S = 0.2729
P/B = 1.0969
P/EG = 7.0492
Revenue TTM = 6.74b USD
EBIT TTM = -42.1m USD
EBITDA TTM = 437.3m USD
Long Term Debt = 2.81b USD (from longTermDebt, last fiscal year)
Short Term Debt = 145.4m USD (from shortTermDebt, last quarter)
Debt = 3.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 378.4m
Net Debt = 3.56b USD (calculated: Debt 3.78b - CCE 214.8m)
Enterprise Value = 5.39b USD (1.83b + Debt 3.78b - CCE 214.8m)
Interest Coverage Ratio = -0.24 (Ebit TTM -42.1m / Interest Expense TTM 178.2m)
EV/FCF = 35.53x (Enterprise Value 5.39b / FCF TTM 151.8m)
FCF Yield = 2.81% (FCF TTM 151.8m / Enterprise Value 5.39b)
FCF Margin = 2.25% (FCF TTM 151.8m / Revenue TTM 6.74b)
Net Margin = -2.49% (Net Income TTM -167.6m / Revenue TTM 6.74b)
Gross Margin = 6.68% ((Revenue TTM 6.74b - Cost of Revenue TTM 6.29b) / Revenue TTM)
Gross Margin QoQ = 9.88% (prev 9.77%)
Tobins Q-Ratio = 0.73 (Enterprise Value 5.39b / Total Assets 7.41b)
Interest Expense / Debt = 4.72% (Interest Expense 178.2m / Debt 3.78b)
Taxrate = 15.79% (2.70m / 17.1m)
NOPAT = -35.5m (EBIT -42.1m * (1 - 15.79%)) [loss with tax shield]
Current Ratio = 1.45 (Total Current Assets 2.20b / Total Current Liabilities 1.51b)
Debt / Equity = 2.20 (Debt 3.78b / totalStockholderEquity, last quarter 1.72b)
Debt / EBITDA = 8.15 (Net Debt 3.56b / EBITDA 437.3m)
Debt / FCF = 23.48 (Net Debt 3.56b / FCF TTM 151.8m)
Total Stockholder Equity = 1.75b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.23% (Net Income -167.6m / Total Assets 7.41b)
RoE = -9.57% (Net Income TTM -167.6m / Total Stockholder Equity 1.75b)
RoCE = -0.92% (EBIT -42.1m / Capital Employed (Equity 1.75b + L.T.Debt 2.81b))
RoIC = -0.61% (negative operating profit) (NOPAT -35.5m / Invested Capital 5.82b)
WACC = 5.53% (E(1.83b)/V(5.61b) * Re(8.75%) + D(3.78b)/V(5.61b) * Rd(4.72%) * (1-Tc(0.16)))
Discount Rate = 8.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.24 | Cagr: -1.95%
[DCF] Terminal Value 77.97% ; FCFF base≈123.2m ; Y1≈141.2m ; Y5≈207.8m
[DCF] Fair Price = N/A (negative equity: EV 3.13b - Net Debt 3.56b = -437.7m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.23 | # QB: 0
Revenue Correlation: 34.81 | Revenue CAGR: 0.66% | SUE: -1.21 | # QB: -2
EPS current Year (2026-12-31): EPS=-0.60 | Chg30d=-29.71% | Revisions=+0% | GrowthEPS=-157.7% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=0.46 | Chg30d=-42.00% | Revisions=-25% | GrowthEPS=+176.8% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: -25% (up=0, down=1)